CD24 Antibody with Great Efficacy and Potency

9月 6, 2022
5:10 下午
Licensing

ID:DT20220511-012 Contact us：bd@drugtimes.cn

最新项目

Usynova Initiates First-in-Human Phase 1 Clinical Trial of Allosteric TYK2 Inhibitor UA021 in Australia

2022-12-27

Phase I 5-HT3 partial agonist with FIC/BIC potential in IBS

2022-10-12

FIC Potential TCR-T/TCE Targeting KRas

2022-09-15

CD24 Antibody with Great Efficacy and Potency

2022-09-06

Leave Your Contact Information, We Will Contact You ASAP.

ALSO FOLLOW US ON

Copyright Reserved © 药时代 Drugtimes 版权所有请勿转载

本站部分文字及图片来源于网络，如侵犯到您的权益，请及时告知并联系 contact@drugtimes.cn，本站将及时处理或撤换，特此声明。